Safety and Effectiveness of Daratumumab in Recurrent and De Novo Focal Segmental Glomerulosclerosis After Kidney Transplant

Daratumumab, an anti-CD38 monoclonal antibody targeting plasma cells, has emerged as a potential therapy for recurrent focal segmental glomerulosclerosis (FSGS) after kidney transplantation; however, data on subcutaneous administration and its use in de novo disease are limited. We report 3 kidney t...

Descrición completa

Detalles Bibliográficos

Principais autores:	Rohan V. Mehta, Kayla B. Evans, Chintan V. Shah, Ashutosh Shukla, Amer Belal, Hisham Ibrahim, Kawther Alquadan, Muhannad Leghrouz, Georgios Vrakas, Rahul Mehta, Alfonso Santos
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2026-07-01
Series:	Kidney Medicine
Assuntos:	Anti-CD38 monoclonal antibody daratumumab focal segmental glomerulosclerosis (FSGS) kidney transplant plasma exchange rituximab
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S2590059526001469
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!